A Phase 3 interventional study of Cevostamab and Pomalidomide in Multiple Myeloma, sponsored by Hoffmann-La Roche. Recruiting at 103 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Multiple Myeloma by Hoffmann-La Roche — 6 open to participants now, 12 under way, 1 of them phase 3. Multiple Myeloma · Hoffmann-La Roche.
Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, this one has the largest planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 28th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →6 of the 30 studies in Multiple Myeloma by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Germany
Ages 18+
Genentech, Inc. · Sites in Australia, Korea, Republic of
Ages 18+
Hoffmann-La Roche · Sites in Australia, France, Germany and 3 more countries
Ages 18+
Genentech, Inc. · Sites in Australia, Israel, Korea, Republic of
Ages 18+
Genentech, Inc. · Sites in United States, Australia, Canada and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 9 · Phase 3 2
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 380 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 90 across the 29 interventional studies, 662 across the 1 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Multiple Myeloma by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05646836Genentech, Inc.A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | 2026-11-18 |
| NCT05535244Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma | 2027-02-26 |
| NCT05927571Genentech, Inc.A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cevostamab will be administered intravenously on a 21-day cycle in cycle 1 and on a 28-day cycle from cycle 2 onwards. Pomalidomide will be administered orally (PO) on a 28-day cycle from cycle 2 onwards. Dexamethasone will be administered as a premedication prior to cevostamab.
Drug: Cevostamab · Drug: Pomalidomide · Drug: Dexamethasone
Participants will receive investigator's choice of one SOC regimen.
Drug: Pomalidomide · Drug: Dexamethasone · Drug: Daratumumab · Drug: Elotuzumab · Drug: Carfilzomib
Participants will receive cevostamab IV as per the schedule given in the protocol.
Participants will receive pomalidomide tablet orally PO as per the schedule given in the protocol.
Participants will receive dexamethasone tablet orally PO or IV as per the schedule given in the protocol.
Participants will receive daratumumab SC as per the schedule given in the protocol.
Participants will receive elotuzumab IV as per the schedule given in the protocol.
Participants will receive carfilzomib IV as per the schedule given in the protocol.
Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate
Time frame: Up to 1 year after the last participant is randomized
Progression-Free Survival (PFS)
Time frame: Up to 5 years after the last participant is randomized
Very Good Partial Response (VGPR) or Better Rate
Time frame: Up to 5 years after the last participant is randomized
Overall Survival (OS)
Time frame: Up to 5 years after the last participant is randomized
Change in Disease Symptoms as Assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Multiple Myeloma Module 20 (MY20)
Primary domains: fatigue, pain, physical functioning, cognitive functioning and global health status.
Time frame: From baseline to Month 6
Overall Response Rate (ORR)
Time frame: Up to 5 years after the last participant is randomized
Complete Response (CR) Rate
Time frame: Up to 5 years after the last participant is randomized
Time to Response (TTR)
Time frame: Up to 5 years after the last participant is randomized
Time to Best Response (TTBR)
Time frame: Up to 5 years after the last participant is randomized
Duration of Response (DOR)
Time frame: Up to 5 years after the last participant is randomized
Progression-Free Survival (PFS)
Time frame: Up to 5 years after the last participant is randomized
Progression-Free Survival 2 (PFS2)
Time frame: Up to 5 years after the last participant is randomized
Overall MRD-Negative Complete Response Rate
Time frame: Up to 5 years after the last participant is randomized
Overall MRD-Negative Rate
Time frame: Up to 5 years after the last participant is randomized
Sustained MRD-Negative CR Rate
Time frame: At 6, 12, and 24 months
Percentage of Participants With Adverse Events (AEs)
Time frame: Up to 5 years after the last participant is randomized
Tolerability as Assessed by the Incidence of Dose Interruptions, Dose Reductions, Dose Intensity, and Treatment Discontinuation
Time frame: Up to 5 years after the last participant is randomized
Number of Participants With Presence, Frequency of Occurrence, Severity, and/or Degree of Interference With Daily Function of Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed NCI PRO-CTCAE
Time frame: Up to 5 years after the last participant is randomized
Change From Baseline in Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE)
Time frame: Baseline and up to 5 years after the last participant is randomized
Change From Cycle 1 Day 8 in Treatment-Related Side Effect Bother as Assessed by the Functional Assessment of Cancer Therapy-General, General Population 5 (FACTG GP5)
Time frame: At Day 8 of Cycle 1, up to 5 years after the last participant is randomized. Cycle 1 is 21 days.
Change From Baseline in the Disease Symptom Scale of the EORTC QLQ-MY20
Time frame: Baseline and Up to 5 years after the last participant is randomized
Change from Baseline in the Global Health Status/Quality of Life (GHS/QoL) of the EORTC QLQ-Core 30 (C30)
Time frame: Baseline and Up to 5 years after the last participant is randomized
Time to Confirmed Deterioration in Disease Symptoms, as Assessed by EORTC QLQ-MY20
Time frame: Up to 5 years after the last participant is randomized
Time to Confirmed Deterioration in GHS/QoL as Assessed by the EORTC QLQ-C30
Time frame: Up to 5 years after the last participant is randomized
Change From Baseline in Fatigue as Assessed by the EORTC QLQ-C30
Time frame: Baseline and up to 5 years after the last participant is randomized
Time to Confirmed Deterioration in Fatigue as Assessed by the EORTC QLQ-C30
Time frame: Up to 5 years after the last participant is randomized
Percentage of Participants Experiencing Clinically Meaningful Improvement in Disease Symptoms as Assessed by the EORTC QLQ-MY20
Time frame: Up to 5 years after the last participant is randomized
Percentage of Participants Experiencing Clinically Meaningful Improvement in GHS/QoL as Assessed by the EORTC QLQ-C30
Time frame: Up to 5 years after the last participant is randomized
Percentage of Participants Experiencing Clinically Meaningful Improvement in Fatigue as Assessed by the EORTC QLQ-C30
Time frame: Up to 5 years after the last participant is randomized
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Cevostamab at Baseline and with ADAs to Cevostamab During the Study
Time frame: Baseline and up to 5 years after the last participant is randomized
Showing the first 100 of 103 sites across 18 countries. Choose a country and city above to see the rest.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Jun 2026 (actual). Primary completion is estimated for Oct 2028, 28 months after the start.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 28 months is below that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cevostamab